Additionally, IPA analysis suggested that FCGR3A is a target of trastuzumab, a monoclonal antibody proposed to treat ALL cases expressing the epidermal growth factor receptor HER2/neu. This receptor has been found to be overexpressed in around 30% of ALL patients and has been associated with chemoresistance and poor clinical outcomes in adults with this malignancy [66,67]. This evidence concerns the gene ERBB2 and acute lymphoblastic leukemia.